Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Immune checkpoint inhibitors (ICIs) offer potential anticancer treatments.
• Tumor resistance and relapse limit ICI efficacy, often due to immunosuppressive cells in the tumor microenvironment (TME).
• Myeloid-derived suppressor cells (MDSCs) are key immunosuppressive cells within the TME, hindering T-cell activity and promoting tumor immune escape.

Purpose of the Study:

• To review the classification and inhibitory functions of MDSCs.
• To explore the crosstalk between MDSCs and other myeloid cells.
• To summarize current therapeutic strategies targeting MDSCs for enhanced cancer immunotherapy.

Main Methods:

• Literature review focusing on myeloid-derived suppressor cells.
• Analysis of MDSC classification and immunosuppressive mechanisms.
• Summary of emerging therapies targeting MDSCs.

Main Results:

• MDSCs are a significant barrier to effective cancer immunotherapy.
• Understanding MDSC function and interactions is crucial for developing new treatments.
• Targeting MDSCs presents a promising strategy to re-engineer the TME and boost anti-cancer immunity.

Conclusions:

• MDSCs play a critical role in tumor-induced immunosuppression.
• Targeting MDSCs offers a potential avenue to overcome resistance to current immunotherapies.
• Further research into MDSC-targeted therapies could significantly improve cancer treatment outcomes.